Loading data for NVAX — first visit, this takes a few seconds.

Alert

Novavax Inc. (NVAX)

NasdaqGS: NVAX · Real-Time Price · USD

9.26

+0.21 (2.32%)

At close: Aug 28, 2026, 8:00 PM

9.27

+0.11%

After-hours: 7:59 PM

The price, the headline numbers and the latest news, in one place.

2.32% (1D)

No data available

Bid	6.59
Market Cap	1.53B
Revenue (ttm)	413.8M
Net Income (ttm)	-247.73M
	2.42
	-1.53
	n/a
	-15.08
P/B (ttm)	-8.00
P/S (ttm)	3.69
Earnings Date	Nov 5, 2026

Ask	11
Volume	4,196,996
Avg. Volume (20D)	4,095,785
Open	9.18
Previous Close	9.05
Day's Range	8.89 - 9.34
52-Week Range	6.20 - 11.97
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About NVAX

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for t...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 5, 1995

Employees 749

Stock Exchange NasdaqGS

Ticker Symbol NVAX

Website https://www.novavax.com

Full Company Profile

Financial Performance

In 2025, Novavax's revenue was 1.12B, an increase of 64.69% compared to the previous year's 682.16M. Earnings were 440.3M, a decrease of -334.83%.

Financial Statements

Earnings Surprise

Novavax has released their quarterly earnings on Aug 6, 2026:

Revenue of $56.7M misses estimates by $0, with -76.30% YoY decline.
EPS of -0.32 exceeds estimates by 0.06, with -151.61% YoY decline.

Next Earnings Release

Novavax Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

3 days ago · Stocktwits

NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open

Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the 2026-2027 COVID season.

3 days ago · GuruFocus.com

Pfizer's Updated COVID Shot Ships Into a Smaller Market

The XFG-adapted vaccine targets older and high-risk patients, with deliveries to pharmacies and clinics beginning immediately.

3 days ago · BioPharma Dive

Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.

5 days ago · Schaeffer's Investment Research

Novavax Stock Pulls Back After Milestone Vaccine Success

Novavax stock is garnering attention from options traders

5 days ago · StockStory

Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how therapeutics stocks fared in Q2, starting with Novavax (NASDAQ:NV...

Page 1 of 2